1. Home
  2. CAN vs ALT Comparison

CAN vs ALT Comparison

Compare CAN & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CAN
  • ALT
  • Stock Information
  • Founded
  • CAN 2013
  • ALT 1997
  • Country
  • CAN Singapore
  • ALT United States
  • Employees
  • CAN N/A
  • ALT N/A
  • Industry
  • CAN Semiconductors
  • ALT Biotechnology: Pharmaceutical Preparations
  • Sector
  • CAN Technology
  • ALT Health Care
  • Exchange
  • CAN Nasdaq
  • ALT Nasdaq
  • Market Cap
  • CAN 330.5M
  • ALT 292.0M
  • IPO Year
  • CAN 2019
  • ALT N/A
  • Fundamental
  • Price
  • CAN $0.74
  • ALT $3.83
  • Analyst Decision
  • CAN Strong Buy
  • ALT Strong Buy
  • Analyst Count
  • CAN 6
  • ALT 6
  • Target Price
  • CAN $2.50
  • ALT $17.40
  • AVG Volume (30 Days)
  • CAN 32.6M
  • ALT 3.0M
  • Earning Date
  • CAN 08-14-2025
  • ALT 08-12-2025
  • Dividend Yield
  • CAN N/A
  • ALT N/A
  • EPS Growth
  • CAN N/A
  • ALT N/A
  • EPS
  • CAN N/A
  • ALT N/A
  • Revenue
  • CAN $345,360,000.00
  • ALT $20,000.00
  • Revenue This Year
  • CAN $90.25
  • ALT N/A
  • Revenue Next Year
  • CAN $42.94
  • ALT $761,880.20
  • P/E Ratio
  • CAN N/A
  • ALT N/A
  • Revenue Growth
  • CAN 82.40
  • ALT N/A
  • 52 Week Low
  • CAN $0.53
  • ALT $2.90
  • 52 Week High
  • CAN $3.27
  • ALT $11.16
  • Technical
  • Relative Strength Index (RSI)
  • CAN 51.63
  • ALT 51.79
  • Support Level
  • CAN $0.64
  • ALT $3.35
  • Resistance Level
  • CAN $0.80
  • ALT $3.66
  • Average True Range (ATR)
  • CAN 0.05
  • ALT 0.19
  • MACD
  • CAN 0.00
  • ALT 0.07
  • Stochastic Oscillator
  • CAN 59.38
  • ALT 86.18

About CAN Canaan Inc.

Canaan Inc is a developer of supercomputing chips and the manufacturer of digital blockchain computing equipment and the supplier of the overall scheme for computer software and hardware of digital blockchain. The revenues of the company are derived from the sales of Bitcoin mining machines and related parts and accessories. Geographically, the company derives its maximum revenue from United States.

About ALT Altimmune Inc.

Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

Share on Social Networks: